Literature DB >> 1847795

The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas.

T Nonami1, K Isshiki, H Katoh, W Kishimoto, A Harada, A Nakao, H Takagi.   

Abstract

The relationship between operative findings of hepatoma and the postoperative prognosis was studied to clarify indications for adjuvant hepatic arterial chemotherapy after hepatectomy. The results of adjuvant hepatic arterial chemotherapy using 0.4 mg/kg of doxorubicin and 0.12 mg/kg of mitomycin C and infusion of 5-fluorouracil were reported. One hundred sixty patients who had undergone hepatectomy for hepatoma were studied. In the operative findings of hepatoma, with a surgical margin of less than 10 mm, intrahepatic metastasis, tumor embolus in the second or more proximal branch of the portal vein, or lack of capsule formation related to the prognosis were the risk factors for recurrence. In 132 patients with these risk factors the survival rate of 19 patients with adjuvant arterial chemotherapy was significantly higher than for the 113 patients without it. Adjuvant hepatic arterial chemotherapy thus may be an effective therapy and should be studied prospectively in patients undergoing hepatectomy for high-risk hepatoma.

Entities:  

Mesh:

Year:  1991        PMID: 1847795      PMCID: PMC1358331          DOI: 10.1097/00000658-199103000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Hepatic resection in 128 patients: a 24-year experience.

Authors:  M E Sesto; D P Vogt; R E Hermann
Journal:  Surgery       Date:  1987-11       Impact factor: 3.982

2.  [Clinico-radiological evaluation of recurrence in the residual liver following hepatectomy in 97 patients with hepatocellular carcinoma].

Authors:  K Takayasu; Y Muramatsu; N Moriyama; T Yamada; H Hasegawa; N Okazaki; S Hirohashi; S Tsugane
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1987-07

3.  Application and results of different chemotherapy regimens in primary liver malignancies.

Authors:  G Falkson; B J Coetzer
Journal:  Recent Results Cancer Res       Date:  1986

4.  Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization.

Authors:  T L Hwang; M F Chen; T Y Lee; T J Chen; D Y Lin; Y F Liaw
Journal:  Arch Surg       Date:  1987-07

5.  Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis.

Authors:  T Nagao; S Inoue; S Goto; T Mizuta; Y Omori; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

6.  Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma.

Authors:  J Shibata; S Fujiyama; T Sato; S Kishimoto; S Fukushima; M Nakano
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

7.  Major liver resection: perioperative course and management.

Authors:  H Ekberg; K G Tranberg; R Andersson; B Jeppsson; S Bengmark
Journal:  Surgery       Date:  1986-07       Impact factor: 3.982

8.  The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol.

Authors:  M L Reed; V K Vaitkevicius; M Al-Sarraf; C B Vaughn; A Singhakowinta; M Sexon-Porte; R Izbicki; L Baker; G W Straatsma
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

9.  Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium.

Authors:  T Konno; H Maeda; K Iwai; S Maki; S Tashiro; M Uchida; Y Miyauchi
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

10.  Clinical management of recurrent hepatocellular carcinoma after primary resection.

Authors:  T Kanematsu; T Matsumata; K Takenaka; Y Yoshida; H Higashi; K Sugimachi
Journal:  Br J Surg       Date:  1988-03       Impact factor: 6.939

View more
  12 in total

1.  Recurrence after resection of alpha-fetoprotein-positive hepatocellular carcinoma.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; B H Yang; J Z Lu; Z Y Lin; Z C Ma; B H Zhang
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 2.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

3.  Prognosis after hepatic resection in patients with hepatocellular carcinoma, estimated on the basis of the morphometric indices.

Authors:  Y Kawai; K Takeshige; M Nunome; H Kuroda; H Suzuki; K Banno; T Koide; H Kobayashi; Y Owa; A Koike
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

5.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; J Wong
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

6.  Results of hepatic resection and postoperative arterial chemotherapy for hepatocellular carcinoma.

Authors:  A Harada; T Nonami; W Kishimoto; A Nakao; H Takagi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Hepatic resection for hepatocellular carcinoma. An audit of 343 patients.

Authors:  E C Lai; S T Fan; C M Lo; K M Chu; C L Liu; J Wong
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

8.  Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy.

Authors:  Wen-Feng Gong; Jian-Hong Zhong; Bang-DE Xiang; LE-Qun Li
Journal:  Mol Clin Oncol       Date:  2016-04-22

9.  Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.

Authors:  M Yasui; T Nonami; T Kurokawa; A Nakao; A Harada; S Hashimoto; M Kajikawa; E Hiraoka; H Takagi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma.

Authors:  M Yasui; A Harada; A Torii; A Nakao; T Nonami; H Takagi
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.